Apogee Therapeutics Announces Upsized $345.1 Million IPO
San Diego – July 18, 2023 – Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company. Partners Div Gupta, Charlie Kim and Kristin VanderPas led the Cooley team advising the underwriters.
Apogee sold 20,297,500 shares of its common stock at a public offering price of $17 per share, less underwriting discounts and commissions, including full exercise of the underwriters’ option to purchase 2,647,500 additional shares. Apogee’s stock began trading on July 14, 2023, under the ticker symbol APGE on the Nasdaq Global Market.
Jefferies, TD Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering.
As of the closing date of this IPO, Cooley worked on four of five US biotechnology IPOs raising at least $20 million in 2023.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.